DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock News
NASDAQ:DAWN - Nasdaq - US23954D1090 - Common Stock - Currency: USD
DAWN Latest News, Press Relases and Analysis
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive...
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now?
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael […]
Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $67.74 as of May 12th. NVO’s trailing and forward P/E were 19.18 and 16.50 respectively according to Yahoo Finance. Novo Nordisk delivered […]
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. Recursion revealed disappointing first-quarter earnings on Monday and announced it would pare down its development pipeline.
NVIDIA Corporation (NVDA): Among Chris Rokos’ Stock Picks with Huge Upside Potential
We recently published an article titled Billionaire Chris Rokos’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where NVIDIA Corporation (NASDAQ:NVDA) stands against Chris Rokos’ other stock picks with huge upside potential. One of the traits that define investors who become billionaires is the ability […]
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 23.91% and 4.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: IMTX
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million ...
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company...
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Relay Therapeutics, Inc. (NASDAQ:RLAY) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on […]
Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the U.S. […]
Why Palantir Stock Is Soaring Today
Shares of Palantir (NASDAQ: PLTR) are surging on Tuesday. The rise comes as the S&P 500 gained 1.4% and the Nasdaq Composite saw significant volatility. President Donald Trump's pledge of a historic trillion-dollar defense budget is fueling investor enthusiasm for the government-focused AI company and defense contractor.
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended...
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company...
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company...
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman’s departure planned for end of 2024 Company’s search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE...
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical...
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term...
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company...